This finding is specially relevant considering that the disease duration of this 2 sub-groups of insulin-treated patients is not different (type 2 diabetes: 45.6 ± 42.8 months; LADA: 46 ± 32.2 months). The gene discussed is INS; the disease is type 2 diabetes mellitus.